|Articles|December 1, 1996

November/December 1996
Volume 2
Issue 11

A Pharmacoeconomic Assessment of Torsemide in the Treatment of Congestive Heart Failure

Author(s)Alan H. Heaton, PharmD, Jeffrey P. Trotter, MM

Download PDF: A Pharmacoeconomic Assessment of Torsemide in the Treatment of Congestive Heart Failure

Articles in this issue

over 29 years ago

Article

The Year in Review

over 29 years ago

Article

Coverage Decisions for Medical Technology by Managed Care: Relationship to Organizational and Physician Payment Characteristics

over 29 years ago

Article

Childhood Immunizations: Beyond HEDIS

over 29 years ago

Article

Implementation of a Clinical Pathway for Cesarean Section

over 29 years ago

Article

Six HMOs in Search of a Study: Comments on Two Papers by Horn et al

over 29 years ago

Article

Homecare Therapy: A Cost-Effective Alternative Approach to the Management of Advanced Heart Failure

over 29 years ago

Article

The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia

over 29 years ago

Article

The Economic and Health-Related Quality of Life Impact of Epilepsy

over 29 years ago

Article

Telecomputing as a Tool to Increase Consumer Participation in Managed Care

over 29 years ago

Article

Impact of Oral Sumatriptan on Workplace Productivity, Health-Related Quality of Life, Healthcare Use, and Patient Satisfaction with Medication in Nurses with Migraine

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

A Pharmacoeconomic Assessment of Torsemide in the Treatment of Congestive Heart Failure

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies